Abstract:Abstract Introduction Polypharmacy is common among postmenopausal women and exposes them to the risks of inappropriate drug use and drug-drug interactions (DDI). Most estrogens are influenced metabolically by drugs which affect key metabolic enzymes. Objective To investigate the DDI potential of E4, several in vitro studies with metabolizing enzymes were performed. A clinical study was also conducted to evaluate the consequence of inhibiting the main enzyme responsible for E4 metabolism. Methods In vitro studies on human hepatocytes or human liver microsomes and recombinant enzymes were conducted to evaluate the role of drug metabolizing enzymes on E4 metabolism [cytochrome P450 enzymes (CYP), UDP-glucuronosyltransferases (UGT) and sulfotransferases (SULT)]. We also assessed the potential of E4 to inhibit or induce these enzymes. Finally, we performed a clinical study to determine the effect of UGT inhibition on the pharmacokinetics (PK) of E4. In this open-label two period, two-way cross-over study, 24 healthy female volunteers received two single doses of a product containing E4 15 mg once alone and once in combination with valproic acid 500 mg twice daily, a strong UGT inhibitor. The consequence of UGT inhibition was quantified by serial plasma measurements of E4 up to 168h after drug administration. Results Effects of other drugs on E4 (E4 as a substrate) CYP enzymes, a superfamily of enzymes that functions as monooxygenases did not play a significant role in the metabolism of E4. Consequently, E4 does not interact with drugs that inhibit or induce CYP enzymes. In vitro and in vivo studies showed that UGT2B7 was the main enzyme involved in E4 glucuronidation and that SULT1 was the dominant enzyme for sulfation of E4. The clinical phase 1 study confirmed the role of UGT in the metabolism of E4. UGT inhibition by valproic acid increased total E4 exposure and maximum concentration only by 1.13 and 1.36-fold, respectively. Because the effect of UGT inhibition on E4 pharmacokinetics is minimal, no clinically relevant effects are expected during coadministration of drugs that inhibit UGT activity. Effect of E4 on other drugs (interference by E4) Studies on the effect of E4 on other drugs showed that E4 neither induces nor inhibits CYP or UGT enzymes, except for a very minimal inhibition of CYP3A4, UGT1A9 and UGT2B7 isoforms. The half maximal inhibitory concentration (IC50) of these in vitro effects were several hundred times above the anticipated clinical maximum concentrations, indicating a low potential for clinically relevant DDIs. Also, there was no evidence of time-dependent inhibition of CYP enzymes. Conclusions Based on these in vitro and in vivo drug interaction studies on metabolizing enzymes, E4 is not expected to have a potential risk for DDI. Unlike other estrogens, CYP enzymes do not play a major role in the metabolism of E4 and can therefore be combined with drugs that inhibit or induce CYP or UGT enzymes without compromising its safety or efficacy. Disclosure Yes, this is sponsored by industry/sponsor: Estetra an affiliate company of Mithra Pharmaceuticals Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Estetra an affiliate company of Mithra Pharmaceuticals.

Hepatic Steroid Sulfatase Critically Determines Estrogenic Activities of Conjugated Equine Estrogens in Human Cells in Vitro and in Mice.

SUN-LB003 the Steroid Sulfatase Dictates the Hormone Replacement Therapy Efficacy of the Conjugated Equine Estrogen

The Effect of 17Β-Estradiol and Its Metabolites on Hepatic Stellate Cells in Rats

Serum Estradiol Levels in Controlled Ovarian Stimulation Directly Affect the Endometrium.

Inflammatory Regulation of Steroid Sulfatase: A Novel Mechanism to Control Estrogen Homeostasis and Inflammation in Chronic Liver Disease.

17Β-Estradiol Suppresses Carboxylesterases by Activating C-Jun/ap-1 Pathway in Primary Human and Mouse Hepatocytes.

Nonnuclear Estrogen Receptor Activation Improves Hepatic Steatosis in Female Mice.

Estrogen Derivatives

Hepatic Overexpression of Steroid Sulfatase Ameliorates Mouse Models of Obesity and Type 2 Diabetes Through Sex-Specific Mechanisms.

The effects of estradiol metabolites on the proliferation and the production of TGF-β1 and CTGF of human hepatic stellate cells

Pharmacokinetic Study of Conjugated Equine Estrogens in Healthy Chinese Postmenopausal Women Using a Parallel Two-Column LC–MS/MS Method

Preclinical Breast Effects of a Tissue Selective Estrogen Complex (TSEC) Including Conjugated Estrogen with Bazedoxifene

Suppressive Effects of 17Beta-Estradiol on Hepatic Fibrosis in CCl4-induced Rat Model.

Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARγ

Soluble ST2 (sst2) As Potential Marker for Hepatic Cystic Echinococcosis Activity.

Mechanisms Enforcing the Estrogen Receptor Β Selectivity of Botanical Estrogens

Protective Effects of Srt1720 Via the Hnf1 Alpha/Fxr Signalling Pathway and Anti-Inflammatory Mechanisms in Mice with Estrogen-Induced Cholestatic Liver Injury

Effects of the Conjugated Equine Estrogen/bazedoxifene Tissue-Selective Estrogen Complex (TSEC) on Mammary Gland and Breast Cancer in Mice.

(068) Low Drug-Drug interaction risk of Estetrol (E4), a Promising New Estrogen for the Treatment of Menopausal Symptoms

Estrogen derivatives: novel therapeutic agents for liver cirrhosis and portal hypertension.

The interaction of estrogen and CSE/H<sub>2</sub>S pathway in the development of atherosclerosis